Table 3.
The perioperative outcomes and oncological outcomes of conventional occlusion technique
| Study | Surgical method | Surgical technique for TT | Case number (L/R) | OT (min), median (range) | EBL (ml), median (range) | Occluded time of IVC (min), median (range) | Complication Grade (n) | Mayo classification (n) | Pathology | Follow-up time (month), median (range) | Prognosis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoang AN et al. [5]. 2010 | LS | CO with a Satinsky or similar clamp | 0/6 | 240 (159–330) | 550 (400–4250) | Na | IV:2 |
II:5 III:1 |
Na | 15 (6–42) | One lung metastasis and died |
| Shao P et al. [19]. 2015 | LS | CO with bulldog clamp (vessel loop) | 0/6 | 155 (135–210) | 275 (150–510) | 16.5 (13–20) | I-II:2 | II:6 | NA | 32.5 (16–52) | Disease free |
| Bratslavsky G et al. [20]. 2015 | RALS | CO with vessel loop | 0/1 | 366 | 1200 | NA | No | III:1 | Clear cell RCC | 20 | Disease free |
| Wang M et al. [13]. 2016 | LS | CO with tourniquet loop | 0/5 | 241 (180–300) (mean) | 290 (50–1000) (mean) | NA | II:1 | II:5 | Clear cell RCC | 11.5 (5–30) (mean) | Lung metastasis |
| Ramirez D et al. [21]. 2016 | RALS | CO with vessel loop | 0/1 | 353 | 150 | 39 | NA | III:1 | Clear cell RCC | NA | NA |
| Chopra S et al. [22]. 2017 | RALS | CO with vessel loop | 7/17 | 270 (180–480) | 240 (100–7000) | 24 (18–102) |
II:2 III:2 |
II:13 III:11 |
RCC:23 Papillary type II RCC:1 |
16 (12–39) | 11 recurrence |
| Wang B et al. [23]. 2018 | RALS | CO with vessel loop | 6/16 | 285 (191–390) | 1350 (1000–2075) | 28.5 (21–31.3) |
I:3 II:5 IV:5 |
II:20 III:2 |
Clear cell RCC:16 Papillary RCC:2 XP11.2-related RCC:1 Carcinoma of the renal pelvis:1 Carcinosarcoma:1 |
16.8 (12–36). | One died, one recurrence, three progressed |
LS laparoscopic surgery; RALS robot-assisted laparoscopic surgery; TT tumor thrombus; L left; R right; OT operative time; EBL estimated blood loss; CO conventional occlusion; NA not available; RCC renal cell carcinoma